Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK

作     者：Carolin Tonus Gero Neupert Markus Sellinger 

作者机构：Herz-Jesu-Hospital Surgical Clinic Buttlarstr. 74 Fulda 36039 Germany Offenbach Municipal Hospital Surgical Clinic Starkenburgring 66 Offenbach 63069 Germany Medical Practice for Gastroenterology and Hepatology Rheing?nheimer Str. 121 Ludwigshafen 67065 Germany 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2006年第12卷第43期

页      面：7007-7011页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Tumor M2-Pyruvate kinase Pyruvate kinasetype M2 Colon cancer Rectal cancer Adenoma Feces Cancer screening 

摘      要：AIM: To evaluate the utility of the innovative fecal tumor M2-Pyruvate kinase (M2-PK) test in our daily clinical routine, as a marker for the pre-selection of patients who should subsequently undergo colonoscopy for the diagnosis or exclusion of colorectal cancer. METHODS: Fecal tumor M2-PK was measured in stool samples of 96 study participants (33 patients with colorectal cancer, 21 patients with rectal carcinoma and 42 controls) who all underwent total colonoscopy. RESULTS: In 39 of 42 individuals in the control group, fecal tumor M2-PK was below 4.0 kU/L (93% specificity). Colorectal tumors were accompanied by a highly significant increase (P 0.001) in fecal tumor M2- PK levels (median: colon carcinoma, 23.1 kU/L; rectal carcinoma, 6.9 kU/L; colorectal carcinoma, 14.7 kU/L), which correlated with Duke’s staging and T-classification. The overall sensitivity was 78% for colorectal cancer, increasing from 60% for stage T1 to 100% for stage T4 and from 60% for Duke’s A to 90% for Duke’s D tumors. CONCLUSION: Fecal tumor M2-PK is an appropriately sensitive tool to pre-select those patients requiring colonoscopy for the further diagnostic confirmation or exclusion of colorectal cancer.